Anthropic's IPO prospectus reveals serious warnings about AI risks, including potential catastrophic harm and rogue behavior from its models. Despite these risks, the company, known for its Claude chatbot, aims for a $2tn valuation with revenue growing 12-fold to $4.6bn in 2025, though operating losses surged to over $8bn. The IPO, expected after the US midterm elections, will test investor confidence in AI amid broader concerns about AI safety and control. Senior AI leaders have also recently warned governments about the dangers of an AI intelligence explosion.
While Anthropic's IPO highlights the high stakes and risks in AI development, AstraZeneca's $2bn cancer drug deal contrasts with steady pharmaceutical sector confidence. On Pluang as of Sep 29, 2026 14:01 WIB, AstraZeneca (AZN) shares are priced at USD 166.15 with no change in the last day. The stock holds a market cap of $257.16 billion and a dividend yield of 1.92%, with strong buy interest at 98% of order activity, reflecting investor trust despite broader market uncertainties.
AstraZeneca is investing $2 billion in Summit Therapeutics to collaborate on cancer drug development, acquiring about 12% of Summit's common stock. The partnership will start clinical trials combining Summit’s ivonescimab with AstraZeneca’s sonesitat...
AstraZeneca PLC has received EU approval for its asthma treatment Trixeo Aerosphere, expanding its market in Respiratory & Immunology. The company leverages mid-single-digit revenue growth into stronger earnings per share gains, driven by its oncolog...
